Key Highlights

  • Novartis (NYSE:NVS) said on November 17, 2026 that the FDA approved Cosentyx 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a steroid taper.
  • Cosentyx becomes the first and only anti-IL-17 biologic approved for the disease, and this is its 11th US indication.
  • In the Phase III REPLENISH trial, Cosentyx doubled the likelihood of sustained remission while patients tapered off steroids.
  • About 966,000 people in the United States live with polymyalgia rheumatica, and up to 40% relapse in the first year.

A New Market for an Established Drug

Novartis (NYSE:NVS) announced the approval of Cosentyx, known generically as secukinumab, in polymyalgia rheumatica, an inflammatory condition that causes pain and stiffness in the shoulders, neck and hips and mainly affects people over 50. Treatment has relied on corticosteroids for decades. Steroids work quickly, but long-term use carries well-known risks, including bone loss, diabetes, weight gain and infection, and many patients relapse when doses are reduced. The approval covers adults whose disease responds inadequately to corticosteroids or who cannot tolerate a steroid taper, a group that represents a substantial share of the roughly 966,000 Americans with the condition, given that relapses affect up to 40% of patients in the first year. Cosentyx blocks interleukin-17A, a signalling protein involved in inflammation, and is already widely used in psoriasis, psoriatic arthritis and axial spondyloarthritis. Polymyalgia rheumatica is its 11th approved US indication, and the first anti-IL-17 approval in the disease, giving Novartis a differentiated position in a field with few targeted options.

What the REPLENISH Trial Showed

The approval rests on REPLENISH, a global, randomized, double-blind, placebo-controlled Phase III trial conducted in 27 countries. Patients received Cosentyx or placebo alongside a structured steroid taper, and the study measured sustained remission, meaning patients stayed free of disease flares while coming off corticosteroids. Novartis said Cosentyx doubled the likelihood of sustained remission compared with placebo while helping patients taper steroids, and the trial also assessed the cumulative steroid dose patients required. The approved dose is 150 mg. Reduced steroid exposure is an important outcome for doctors and payers because complications from long-term steroid use generate significant costs. The indication is already approved in the European Union, and a review is under way in Japan, which means the opportunity extends beyond the United States. For a company focused on extending the life of its key franchises, a new population of older patients with a chronic condition offers incremental Revenue at relatively low additional development cost, while also deepening relationships with rheumatologists who already prescribe the drug for other conditions.

Commercial Outlook and Risks

Cosentyx is one of the largest products in the portfolio of Novartis (NYSE:NVS), so each new indication helps protect revenue as competition intensifies. The polymyalgia rheumatica opportunity is meaningful but should be kept in perspective. Uptake will depend on rheumatologists' willingness to move patients from inexpensive steroids to a costly biologic, on insurer coverage policies, which may require patients to Fail steroid treatment first, and on the convenience of dosing. Competing therapies, including an IL-6 inhibitor already approved in the disease, will vie for the same patients. Over the longer term, biosimilar versions of Cosentyx are expected later in the decade, which will pressure pricing across all indications. For investors, the approval supports Novartis's strategy of building growth from its existing immunology Franchise while advancing newer medicines. Early prescription data in 2027 and any updated peak-sales commentary from management will indicate how much the new label adds.

Where Things Stand

The FDA approval makes Cosentyx the first anti-IL-17 biologic for polymyalgia rheumatica and adds a steroid-sparing option for a large, underserved population. The label is the drug's 11th in the United States and follows approval in Europe. Prescription uptake and payer coverage will determine its commercial value.